CXCR4 and pancreatic neoplasm: Finally, nine studies that were published between 2000 and 2013 were eligible for our meta-analysis that aimed to elucidate the impact of CXCR4 as a prognostic and clinicopathological biomarker in pancreatic cancer [6, 16, 17, 36–41].